Back to News
Market Impact: 0.2
BrainsWay Reports Positive Pilot Study Results For Deep TMS In Depression & Early Alzheimer's
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
BrainsWay reported a peer-reviewed pilot study evaluating its Deep TMS technology in patients with major depressive disorder and comorbid early-stage Alzheimer's disease. The article did not disclose efficacy, safety, or financial results, limiting the immediate valuation impact, but the study supports ongoing clinical validation of the company's neurostimulation platform.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
BWAY0.45
More News
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Elon Musk’s dangerous grip on outer space
- J&J prostate cancer drug shows promising tumor responses in early trial
- Ukraine Says Restrictions on Starlink Speed Have Been Lifted
- AI agents could disrupt bank deposits. Why Wall Street may be overreacting
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?
- Earnings-Triggered Research Automations: A Control Guide